BusinessAsianet Newsable
HIMS Stock Rises Overnight: Retail Traders Bet On Peptides Upside After FDA Panel Backs 6 Of 7 Compounds
in5points
HIMS stock rose after an FDA advisory panel backed six of seven peptides for the 503A compounding list.
Emideltide was the only peptide rejected by the panel.
Retail traders are betting on upside for HIMS related to peptides.
Story angle
Center
L
CL
C
CR
R
Near the middle: closer to straight reporting, less party-line spin.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically